Transcriptomics

Dataset Information

5

Effect of Sunitinib treatment withdrawal on Immunodeficient mice bearing MDA-MB231 tumors


ABSTRACT: Immunodeficient RAG1-/- mice bearing MDA-MB231-LUC+ tumors of 50-70 mm3 were daily administrated by gavage with vehicle (containing, 0.5% carboxymethylcellulose, 1.8 % NaCl, 0.4 % Tween-80, 0.9 %. benzyl alcohol, and ultrapure water adjusted to pH 6.0) or sunitinib (40mg/kg/day) for 30 days followed by treatment withdrawal for 3-4 weeks to allow the tumor regrowth until reaching the same volume as that of the vehicle treated group. Mice were sacrificed when tumor reached the volume of 350-400 mm3 and RNAs of two tumors from two different mice treated with sunitinib or vehicle were extracted. One color experiment with 2 experimental conditions: Sunitinib vs Vehicle (n=2), corresponding to a total of 4 samples.

ORGANISM(S): Mus musculus  

SUBMITTER: K Lebrigand   A Noel  P Barbry  Kevin Lebrigand  B Mari 

PROVIDER: E-GEOD-50795 | ArrayExpress | 2014-08-24

SECONDARY ACCESSION(S): GSE50795PRJNA218954

REPOSITORIES: GEO, ArrayExpress

altmetric image

Publications


The molecular mechanisms responsible for the failure of antiangiogenic therapies and how tumors adapt to these therapies are unclear. Here, we applied transcriptomic, proteomic, and metabolomic approaches to preclinical models and provide evidence for tumor adaptation to vascular endothelial growth factor blockade through a metabolic shift toward carbohydrate and lipid metabolism in tumors. During sunitinib or sorafenib treatment, tumor growth was inhibited and tumors were hypoxic and glycolytic  ...[more]

Similar Datasets

2016-07-06 | E-GEOD-84048 | ArrayExpress
| GSE66346 | GEO
2015-06-26 | E-GEOD-70282 | ArrayExpress
2015-12-17 | E-GEOD-76068 | ArrayExpress
2011-02-26 | E-TABM-929 | ArrayExpress
| GSE69535 | GEO
| GSE122820 | GEO
2013-02-11 | E-GEOD-32099 | ArrayExpress
| GSE122819 | GEO
| GSE122821 | GEO